玉屏风散联合常规疗法治疗小儿心肌酶谱异常慢性持续期支气管哮喘疗效观察  

Treating Chronic Persistent Bronchial Asthma Children with Abnormal Myocardial Enzyme Spectrum by Yupingfeng Powder:an Efficacy Observation

作　　者：陈啸洪[1] 李华浚[1] 张佩红[1] 章杭湖[1] 郭航远[2] 

机构地区：[1]浙江省绍兴市人民医院儿内科,浙江312000 [2]浙江省绍兴市人民医院心内科,浙江312000

出　　处：《中国中西医结合杂志》2014年第5期518-521,共4页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：绍兴市科技计划项目(No.2012B70069)

摘　　要：目的观察玉屏风散联合常规疗法对小儿心肌酶谱异常慢性持续期支气管哮喘疗效。方法选择156例心肌酶谱异常的慢性持续期支气管哮喘患儿,随机分为治疗组(80例)和对照组(76例),两组均给予常规治疗[吸入皮质激素和(或)白三烯调节剂],治疗组加用玉屏风散,两组均治疗3个月。检测两组治疗前、治疗后及治疗后3个月临床症状评分(C-ACT)、肺功能(FEV1%、PEF%)、心肌酶谱,并选择同期儿童保健门诊体验的健康儿童40名心肌酶谱为对照。结果与健康组比较,两个用药组患儿CK-MB、CK、LDH均升高(P<0.01),AST差异无统计学意义(P>0.05)。与本组治疗前比较,治疗组治疗后及治疗后3个月CK-MB、CK、LDH、AST均降低(P<0.01,P<0.05);对照组治疗后3个月CK-MB、CK、LDH、AST均降低(P<0.01,P<0.05);两组治疗后及治疗后3个月C-ACT评分、FEV1%、PEF%均升高(P<0.01,P<0.05)。与本组治疗后比较,对照组治疗后3个月CK降低(P<0.01)。与对照组同期比较,治疗组治疗后CK-MB、CK降低(P<0.01,P<0.05),C-ACT评分、FEV1%及PEF%升高(P<0.05)。结论玉屏风散能增强机体特异性和非特异性免疫,改善临床症状及心肌酶谱。Objective To observe the clinical efficacy of treating chronic persistent bronchial asth- ma （CPBA） children with abnormal myocardial enzyme spectrum （AMES） by Yupingfeng Powder （YP） combined routine therapy. Methods From January 2010 to December 2012, 156 CPBA children patients with AMES were randomly assigned to the treatment group （80 cases） and the control group （76 cases）. All patients received routine treatment （inhaled corticosteroids and/or leukotriene regulator）. Besides, those in the treatment group took YP. The treatment duration was 3 months. The scores of children asthma control test （C-ACT）, pulmonary function （FEV~% and PEF%）, myocardial enzyme spectrum were observed before and after treatment, and 3 months before and after treatment. The myocardial enzyme spectrum of 40 healthy children at the baby clinics during the same period were recruited as the control. Results Compared with the control group, creatine kinase isoenzyme （CK-MB）, creatine kinase （CK）, and lactate dehydrogenase （LDH） increased in the two treatment groups （P 〈0.01 ）, but there was no statistical difference in AST （P 〉0.05）. Compared with before treatment in the same group, CK-MB, CK, LDH, and AST decreased in the treatment group after treat- ment and 3 months after treatment （P 〈0.01 ）. CK-MB, CK, LDH, and AST decreased in the control group 3 months after treatment （P 〈0. 01, P 〈0.05）. Compared with after treatment, CK decreased in the control group 3 months after treatment （P 〈0.01 ）. C-ACT score, FEV1%, and PEF% all increased in the two groups after treatment and 3 months after treatment （P 〈0. 01, P 〈0. 05）. Compared with after treatment in the same group, CK decreased in the control group 3 months after treatment （P 〈0.01 ）. Compared with the control group in the same period, post-treatment CK-MB and CK decreased （P 〈 0. 01, P 〈 0.05）, while post-treatment C-ACT score, FEV1%, and PEF% increased （P 〈0.05） in the treatment g

关 键 词：玉屏风散 支气管哮喘 慢性持续期 心肌酶谱 

分 类 号：R725.6[医药卫生—儿科]